Back to Search Start Over

Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial.

Authors :
Alexander RB
Propert KJ
Schaeffer AJ
Landis JR
Nickel JC
O'Leary MP
Pontari MA
McNaughton-Collins M
Shoskes DA
Comiter CV
Datta NS
Fowler JE Jr.
Nadler RB
Zeitlin SI
Knauss JS
Wang Y
Kusek JW
Nyberg LM Jr.
Litwin MS
Chronic Prostatitis Collaborative Research Network
Source :
Annals of Internal Medicine; 10/19/2004, Vol. 141 Issue 8, p581-I8, 10p
Publication Year :
2004

Abstract

<bold>Background: </bold>Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in men is principally defined by pain in the pelvic region lasting more than 3 months. No cause of the disease has been established, and therapies are empirical and mostly untested. Antimicrobial agents and alpha-adrenergic receptor blockers are frequently used.<bold>Objective: </bold>To determine whether 6-week therapy with ciprofloxacin or tamsulosin is more effective than placebo at improving symptoms in men with refractory, long-standing CP/CPPS.<bold>Design: </bold>Randomized, double-blind trial with a 2 x 2 factorial design comparing 6 weeks of therapy with ciprofloxacin, tamsulosin, both drugs, or placebo.<bold>Setting: </bold>Urology outpatient clinics at 10 tertiary care medical centers in North America.<bold>Patients: </bold>Patients were identified from referral-based practices of urologists. One hundred ninety-six men with a National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score of at least 15 and a mean of 6.2 years of symptoms were enrolled. Patients had received substantial previous treatment.<bold>Measurements: </bold>The authors evaluated NIH-CPSI total score and subscores, patient-reported global response assessment, a generic measure of quality of life, and adverse events.<bold>Interventions: </bold>Ciprofloxacin, 500 mg twice daily; tamsulosin, 0.4 mg once daily; a combination of the 2 drugs; or placebo.<bold>Results: </bold>The NIH-CPSI total score decreased modestly in all treatment groups. No statistically significant difference in the primary outcome was seen for ciprofloxacin versus no ciprofloxacin (P = 0.15) or tamsulosin versus no tamsulosin (P > 0.2). Treatments also did not differ significantly for any of the secondary outcomes.<bold>Limitations: </bold>Treatment lasting longer than 6 weeks was not tested. Patients who had received less pretreatment may have responded differently.<bold>Conclusion: </bold>Ciprofloxacin and tamsulosin did not substantially reduce symptoms in men with long-standing CP/CPPS who had at least moderate symptoms. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00034819
Volume :
141
Issue :
8
Database :
Complementary Index
Journal :
Annals of Internal Medicine
Publication Type :
Academic Journal
Accession number :
106585876
Full Text :
https://doi.org/10.7326/0003-4819-141-8-200410190-00005